參考文獻(xiàn)
1. 國務(wù)院應(yīng)對新型冠狀病毒肺炎疫情聯(lián)防聯(lián)控機(jī)制綜合組,《關(guān)于進(jìn)一步優(yōu)化新冠肺炎疫情防控措施科學(xué)精準(zhǔn)做好防控工作的通知》 (2022)
2. 國務(wù)院應(yīng)對新型冠狀病毒肺炎疫情聯(lián)防聯(lián)控機(jī)制綜合組,《關(guān)于進(jìn)一步優(yōu)化落實(shí)新冠肺炎疫情防控措施的通知》(2022)
3. 國家衛(wèi)生健康委員會,《新型冠狀病毒肺炎診療方案(試行第九版)》(2022)
4. 國家衛(wèi)生健康委員會,《新型冠狀病毒肺炎防控方案(第九版)》(2022)
5. 國家衛(wèi)生健康委員會,《關(guān)于印發(fā)新冠病毒感染者居家治療指南的通知》(2022)
6. 國家衛(wèi)生健康委員會,《新冠病毒疫苗第二劑次加強(qiáng)免疫接種實(shí)施方案》(2022)
7. World Health Organization. COVID-19 Weekly Epidemiological Update. World Heal. Organ. 1–33 (2022).
8. SARS-CoV-2 variants of concern as of 3 December 2021. European Centre for Disease Prevention and Control https://www.ecdc./en/covid-19/variants-concern (2021).
9. Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments. CDC COVID-19 Science Briefs http://www.ncbi.nlm./pubmed/34009771 (2020).
10. Lewis, D. Why the WHO took two years to say COVID is airborne. Nature 604, 26–31 (2022).
11. Hirose, R. et al. Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19. Clin. Infect. Dis. 1–27 (2020).
12. Kim, D. et al. The Architecture of SARS-CoV-2 Transcriptome. Cell 181, 914-921.e10 (2020).
13. Talic, S. et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: Systematic review and meta-analysis. BMJ 375, (2021).
14. Yan, W. et al. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct. Target. Ther. 7, (2022).
15. Chilamakuri, R. & Agarwal, S. Covid-19: Characteristics and therapeutics. Cells 10, 1–29 (2021).
16. Lambrou, A. S. et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022. MMWR Recomm. Reports 71, 206–211 (2022).
17. He, X.et al. SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm 2, 838–845 (2021).
18. Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607, 119–127 (2022).
19. Puhach, O., Meyer, B. & Eckerle, I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. (2022).
20. Fan, Y. et al. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct. Target. Ther. 7,141 (2022).
21. Drain P.K. Rapid Diagnostic Testing for SARS-CoV-2. N. Engl. J. Med. 386, 264 - 272(2022).
22. Cevik, M. et al. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 371,m3862 (2020).
23. Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2021).
24. Lu, G. et al. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerg. Microbes Infect. 11, 2045–2054 (2022).
25. Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 1532–1546 (2022).
26. Ranzani, O. T. et al. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nat. Commun. 13, 5536 (2022).
27. Eyre, D. W. et al. Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants. N. Engl. J. Med. 386, 744–756 (2022).